BackgroundThe PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell lung c Abstract Background: The PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell...
AbstractPurpose Leptomeningeal metastasis (LM) carries a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to explore clinical features and survival outcomes and develop a nomogram for overall survival (OS) in this population. Methods We retrospectively enrolled...
AbstractPurpose Ramucirumab plus FOLFIRI is an established second-line treatment option for metastatic colorectal cancer (mCRC) after oxaliplatin-based first-line therapy. However, real-world data comparing outcomes according to prior biologic exposure are limited. Methods We retrospectively reviewed patients with mCRC who received...
AbstractBackground To develop and validate a contrast-enhanced ultrasound (CEUS)-based habitat model for noninvasive prediction of epidermal growth factor receptor (EGFR) mutation status in patients with peripheral non-small cell lung cancer (NSCLC). Methods This retrospective study included 187 patients with NSCLC...
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as...
This is a paid press release. Contact the press release distributor directly with any inquiries. Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer PR Newswire Thu, June 25, 2026 at...
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as...
BackgroundObesity, hyperinsulinemia, and type 2 diabetes mellitus (T2DM) are considered adverse metabolic conditions in cancer, although exceptions like the Abstract Background: Obesity, hyperinsulinemia, and type 2 diabetes mellitus (T2DM) are considered adverse metabolic conditions in cancer, although exceptions like the...
Abstract To investigate the regulatory effects of cryptotanshinone (CTS) on the biological behavior of glioma cells and its underlying molecular mechanisms, with a particular focus on the role of the epidermal growth factor receptor/reactive oxygen species (EGFR/ROS) pathway in ferroptosis-mediated...
AbstractBackground One of the main reasons of disability and death is stroke in China and other countries, with growing evidence pointing to the role of microglial polarization in its pathogenesis. Epidermal growth factor receptor as well as Glycoprotein non-metastatic melanoma...
